A Phase 3 interventional study of Placebo and Tramadol-single dose in Acute Pain, sponsored by Menarini Group. Completed at 37 sites in 10 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-03-07.
Sponsored by Menarini Group · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Acute Pain with a site in Poland — 1 open to participants now, 1 under way, none of them phase 3. Acute Pain · Poland.
Among the 19 studies in Acute Pain with a site in Poland, this one is the 4th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2013, is one of 6 in phase 3, and was the 1st registered.
1,075 studies on the registry are indexed under Acute Pain; 168 are open to participants now.
Browse Acute Pain studies →1 of the 19 studies in Acute Pain with a site in Poland is open now. Recruiting first, the newest first:
Medical University of Warsaw · Sites in Poland
Ages 3–18
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 641 is above the median of 86 across 903 interventional studies indexed under Acute Pain.
Median enrollment 158 across the 18 interventional studies, 59 across the 1 observational. Of the 17 that completed or were terminated, 4 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 19 have an industry lead sponsor. The 10 most frequent:
Menarini Group is the lead sponsor of 28 studies on the registry; 1 is open to participants now.
Menarini Group has 4 studies filed under Acute Pain — fewer than ten, so there is no comparison to draw.
1 of the studies in Acute Pain with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07024199Medical University of WarsawComparison of the Effectiveness of Paracetamol With Ibuprofen or Paracetamol With Metamizole in Treating Pain in Acute Pancreatitis in Children | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Acute Pain with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the analgesic efficacy of single and repeated doses of fixed combination of dexketoprofen trometamol (DKP) and tramadol hydrochloride (TRAM) in comparison to the single agents (and placebo for the single dose phase only) Approximately 600 male and female patients presenting moderate to severe pain after an elective primary hip arthroplasty are eligible to be randomised provided that they experience moderate to severe pain on the day after surgery.
In this clinical trial patients were randomized to the described 6 treatment arms, where each arm define the treatment to be received in the first single dose phase (lasting 8 hours after the 1st treatment intake) and in the subsequent multiple-dose phase (lasting from the second treatment intake up to the 8 hours after the last intake). Namely:
The analyses of endpoints pertinent to the single dose phase were performed combining all the 3 treatment arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.
The analysis of endpoints pertinent to the multiple dose phase were performed combining the treatment arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dexketoprofen/Tramadol-single dose followed by Dexketoprofen/Tramadol-multiple doses
Drug: Dexketoprofen/Tramadol-single dose · Drug: Dexketoprofen/Tramadol-multiple doses
Dexketoprofen-single dose followed by Dexketoprofen-multiple doses
Drug: Dexketoprofen-single dose · Drug: Dexketoprofen-multiple doses
Tramadol-single dose followed by Tramadol-multiple doses
Drug: Tramadol-single dose · Drug: Tramadol-multiple doses
Placebo single dose followed by Dexketoprofen/Tramadol-multiple doses
Drug: Placebo · Drug: Dexketoprofen/Tramadol-multiple doses
Placebo single dose followed by Dexketoprofen-multiple doses
Drug: Placebo · Drug: Dexketoprofen-multiple doses
Placebo single dose followed by Tramadol-multiple doses
Drug: Placebo · Drug: Tramadol-multiple doses
Placebo single oral dose (first 8 hours)
Tramadol single oral dose (first 8 hours)
Dexketoprofen single oral dose (first 8 hours)
Dexketoprofen/Tramadol oral single dose (first 8 hours)
Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
Dexketoprofen multiple oral doses t.i.d. for 5 days (total 12 doses)
Dexketoprofen/Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
SPID8 (Sum of Pain Intensity Differences Over 8 Hours)
Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 8 hour period. PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, and 8h after the first dose. A higher value in SPID indicates greater pain relief. The analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.
Time frame: over 8 hours after the first dose
SPID48 (Sum of Pain Intensity Differences Over First 48 Hours of the Multiple-dose Phase)
Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 48 hours of the multiple-dose phase. PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured every two hours over the first 48 hours of the multiple-dose phase. A higher value in SPID indicates greater pain relief. The analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.
Time frame: over 48 hours of the multiple-dose phase
Percentage of Responders According to PI-VAS (Pain Intensity - Visual Analogue Scale)
Percentage of responders; response defined as achievement a mean pain intensity, PI-VAS \< 40 mm (PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale, 0=no pain to 100=worst pain imaginable),over 48 hours of the multiple-dose phase. The analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.
Time frame: over 48 hours of the multiple-dose phase
Percentage of Responders According to 50% Max TOTPAR (Total Pain Relief)
Percentage of responders over 8 hours after first dose, according to the 50% maximum total pain relief rule: maximum TOTPAR calculated as the theoretical maximum weighted sum of PAR-VRS (Pain Relief - Verbal Rating Scale: pain relief 0=none, 4=complete) scores. The analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.
Time frame: over 8 hours after the first dose
| Milestone | DKP/TRAM Followed by DKP/TRAM | DKP Followed by DKP | TRAM Followed by TRAM | Placebo Followed by DKP/TRAM | Placebo Followed by DKP | Placebo Followed by TRAM |
|---|---|---|---|---|---|---|
| Started | 159 | 161 | 160 | 54 | 53 | 54 |
| Single-dose phase | 159 | 161 | 160 | 54 | 53 | 54 |
| Multiple-dose phase | 159 | 160 | 160 | 54 | 53 | 52 |
| Completed | 151 | 150 | 145 | 52 | 46 | 45 |
| Not completed | 8 | 11 | 15 | 2 | 7 | 9 |
| Withdrew: Adverse event | 3 | 1 | 2 | 1 | 1 | 3 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 4 | 8 | 9 | 1 | 5 | 4 |
| Withdrew: No compliance | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 2 | 0 | 1 | 0 |
Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 8 hour period. PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, and 8h after the first dose. A higher value in SPID indicates greater pain relief. The analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.
| units on a scale | DKP/TRAM | DEXKETOPROFEN | TRAMADOL | PLACEBO |
|---|---|---|---|---|
| SPID8 (Sum of Pain Intensity Differences Over 8 Hours) | 246.9 ± 156.50 | 208.8 ± 154.69 | 204.6 ± 145.79 | 151.1 ± 158.51 |
Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 48 hours of the multiple-dose phase. PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured every two hours over the first 48 hours of the multiple-dose phase. A higher value in SPID indicates greater pain relief. The analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.
| units on a scale | DKP/TRAM | DEXKETOPROFEN | TRAMADOL |
|---|---|---|---|
| SPID48 (Sum of Pain Intensity Differences Over First 48 Hours of the Multiple-dose Phase) | 1943.7 ± 1000.51 | 1677.5 ± 1070.91 | 1765.6 ± 963.49 |
Percentage of responders; response defined as achievement a mean pain intensity, PI-VAS \< 40 mm (PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale, 0=no pain to 100=worst pain imaginable),over 48 hours of the multiple-dose phase. The analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.
| percentage of participants | DKP/TRAM | DEXKETOPROFEN | TRAMADOL |
|---|---|---|---|
| Percentage of Responders According to PI-VAS (Pain Intensity - Visual Analogue Scale) | 90.1 | 76.6 | 82.2 |
Percentage of responders over 8 hours after first dose, according to the 50% maximum total pain relief rule: maximum TOTPAR calculated as the theoretical maximum weighted sum of PAR-VRS (Pain Relief - Verbal Rating Scale: pain relief 0=none, 4=complete) scores. The analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.
| percentage of participants | DKP/TRAM | DEXKETOPROFEN | TRAMADOL | PLACEBO |
|---|---|---|---|---|
| Percentage of Responders According to 50% Max TOTPAR (Total Pain Relief) | 57.9 | 56.5 | 51.9 | 37.9 |
Collected over Study duration for patients was up to 6 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DKP/TRAM Followed by DKP/TRAM | — | 2/159 (1.3%) | 15/159 (9.4%) |
| DKP Followed by DKP | — | 3/161 (1.9%) | 18/161 (11.2%) |
| TRAM Followed by TRAM | — | 1/160 (0.6%) | 24/160 (15%) |
| Placebo Followed by DKP/TRAM | — | 1/54 (1.9%) | 9/54 (16.7%) |
| Placebo Followed by DKP | — | 0/53 (0%) | 2/53 (3.8%) |
| Placebo Followed by TRAM | — | 0/54 (0%) | 5/54 (9.3%) |
| Event | DKP/TRAM Followed by DKP/TRAM | DKP Followed by DKP | TRAM Followed by TRAM | Placebo Followed by DKP/TRAM | Placebo Followed by DKP | Placebo Followed by TRAM |
|---|---|---|---|---|---|---|
| Soft tissue infectionInfections and infestations | 0/159 | 0/161 | 0/160 | 1/54 | 0/53 | 0/54 |
| Heart valve replacementSurgical and medical procedures | 1/159 | 0/161 | 0/160 | 0/54 | 0/53 | 0/54 |
| Vascular graftSurgical and medical procedures | 1/159 | 0/161 | 0/160 | 0/54 | 0/53 | 0/54 |
| Face oedemaGeneral disorders | 1/159 | 0/161 | 0/160 | 0/54 | 0/53 | 0/54 |
| Laryngeal oedemaRespiratory, thoracic and mediastinal disorders | 1/159 | 0/161 | 0/160 | 0/54 | 0/53 | 0/54 |
| Cardiac disorderCardiac disorders | 1/159 | 0/161 | 0/160 | 0/54 | 0/53 | 0/54 |
| Periorbital oedemaEye disorders | 1/159 | 0/161 | 0/160 | 0/54 | 0/53 | 0/54 |
| HaematuriaRenal and urinary disorders | 1/159 | 0/161 | 0/160 | 0/54 | 0/53 | 0/54 |
| Bone operationSurgical and medical procedures | 0/159 | 1/161 | 1/160 | 0/54 | 0/53 | 0/54 |
| Device dislocationGeneral disorders | 0/159 | 0/161 | 1/160 | 0/54 | 0/53 | 0/54 |
| Event | DKP/TRAM Followed by DKP/TRAM | DKP Followed by DKP | TRAM Followed by TRAM | Placebo Followed by DKP/TRAM | Placebo Followed by DKP | Placebo Followed by TRAM |
|---|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 3/159 | 9/161 | 11/160 | 3/54 | 2/53 | 4/54 |
| NauseaGastrointestinal disorders | 2/159 | 4/161 | 9/160 | 1/54 | 0/53 | 0/54 |
| Anaemia postoperativeInjury, poisoning and procedural complications | 7/159 | 6/161 | 5/160 | 3/54 | 0/53 | 0/54 |
| AnaemiaBlood and lymphatic system disorders | 3/159 | 1/161 | 1/160 | 3/54 | 0/53 | 1/54 |
Intention-to-treat (ITT) population (which includes all patients randomized).
| Age, Continuous(years) | DKP/TRAM Followed by DKP/TRAM | DKP Followed by DKP | TRAM Followed by TRAM | Placebo Followed by DKP/TRAM | Placebo Followed by DKP | Placebo Followed by TRAM | Total |
|---|---|---|---|---|---|---|---|
| Mean | 61.3 ± 10.43 | 63.3 ± 9.01 | 61.3 ± 9.68 | 63.9 ± 9.0 | 61.0 ± 11.10 | 59.8 ± 11.30 | 61.9 ± 9.96 |
| Sex: Female, Male(Participants) | DKP/TRAM Followed by DKP/TRAM | DKP Followed by DKP | TRAM Followed by TRAM | Placebo Followed by DKP/TRAM | Placebo Followed by DKP | Placebo Followed by TRAM | Total |
|---|---|---|---|---|---|---|---|
| Female | 86 | 86 | 80 | 37 | 33 | 24 | 346 |
| Male | 73 | 75 | 80 | 17 | 20 | 30 | 295 |
| Race/Ethnicity, Customized(participants) | DKP/TRAM Followed by DKP/TRAM | DKP Followed by DKP | TRAM Followed by TRAM | Placebo Followed by DKP/TRAM | Placebo Followed by DKP | Placebo Followed by TRAM | Total |
|---|---|---|---|---|---|---|---|
| Asian | 0 | 2 | 3 | 0 | 0 | 2 | 7 |
| White | 159 | 159 | 157 | 54 | 53 | 52 | 634 |
| Region of Enrollment(participants) | DKP/TRAM Followed by DKP/TRAM | DKP Followed by DKP | TRAM Followed by TRAM | Placebo Followed by DKP/TRAM | Placebo Followed by DKP | Placebo Followed by TRAM | Total |
|---|---|---|---|---|---|---|---|
| Serbia | 15 | 18 | 14 | 5 | 5 | 5 | 62 |
| Taiwan | 0 | 2 | 3 | 0 | 0 | 2 | 7 |
| Czech Republic | 9 | 10 | 8 | 2 | 4 | 3 | 36 |
| Hungary | 49 | 57 | 54 | 17 | 16 | 11 | 204 |
| Spain | 1 | 0 | 1 | 0 | 0 | 0 | 2 |
| Poland | 10 | 8 | 8 | 2 | 2 | 3 | 33 |
| Ukraine | 15 | 13 | 13 | 6 | 6 | 3 | 56 |
| Lithuania | 22 | 19 | 21 | 6 | 5 | 11 | 84 |
| Germany | 1 | 1 | 2 | 0 | 0 | 0 | 4 |
| Latvia | 37 | 33 | 36 | 16 | 15 | 16 | 153 |
| Weight(kg) | DKP/TRAM Followed by DKP/TRAM | DKP Followed by DKP | TRAM Followed by TRAM | Placebo Followed by DKP/TRAM | Placebo Followed by DKP | Placebo Followed by TRAM | Total |
|---|---|---|---|---|---|---|---|
| Mean | 83.3 ± 15.37 | 81.4 ± 15.63 | 83.5 ± 17.25 | 82.4 ± 15.91 | 81.7 ± 13.77 | 82.1 ± 15.27 | 82.6 ± 15.80 |
| Height(cm) | DKP/TRAM Followed by DKP/TRAM | DKP Followed by DKP | TRAM Followed by TRAM | Placebo Followed by DKP/TRAM | Placebo Followed by DKP | Placebo Followed by TRAM | Total |
|---|---|---|---|---|---|---|---|
| Mean | 168.8 ± 8.99 | 167.9 ± 9.14 | 169.1 ± 9.20 | 166.1 ± 8.47 | 168.0 ± 9.49 | 169.9 ± 7.94 | 168.5 ± 9.01 |
The record gives a start of Apr 2013, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.